Research programme: phospholipase A2 inhibitors therapeutics - Ophirex

Drug Profile

Research programme: phospholipase A2 inhibitors therapeutics - Ophirex

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ophirex
  • Class Anti-inflammatories; Antidotes; Antivenins
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Snake venom poisoning

Most Recent Events

  • 01 Sep 2017 Ophirex in-licenses sPLA2 inhibitors data from Eli Lilly and Shionogi for Snake venom poisoning
  • 29 Aug 2017 Preclinical trials in Snake venom poisoning in USA (Parenteral) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top